Xiaoling Ma | Medicine | Best Researcher Award

Prof. Xiaoling Ma | Medicine | Best Researcher Award

Chief physician | The first hospital of Lanzhou university | China

Dr. Xiaoling Ma is a distinguished Chief Physician and Associate Professor, currently serving as the Director of the Reproductive Medicine Center at The First Hospital of Lanzhou University. With over two decades of experience in reproductive medicine, she has made significant contributions to the advancement of assisted reproductive technology (ART). Dr. Ma is a nationally recognized expert in ART management and holds key positions in several prestigious reproductive medicine organizations in China. Her expertise encompasses reproductive endocrinology, fertility preservation, and genetic screening technologies.

Profile👤

Scopus

Strengths for the Awards✨

Extensive Research Contributions: Xiaoling Ma has published over 30 articles in SCI and core Chinese journals, indicating a strong research output. Recent publications in Biomedicine & Pharmacotherapy, Reproductive Sciences, and BMC Medical Genomics highlight her contributions to reproductive medicine.

Leading Research and Innovation: She has led multiple national and provincial research projects, including studies on reproductive genetics, fertility preservation, and endometriosis mechanisms.

Academic and Professional Influence: As a chief physician, associate professor, and director of the Reproductive Medicine Center, her influence extends to clinical practice, academic mentorship, and policy advisory roles.

Editorial and Professional Leadership: Serving as the Chinese editor for Human Reproduction Update and holding key roles in reproductive medicine associations in China demonstrate her leadership in the field.

🎓 Education

Dr. Xiaoling Ma obtained her Master’s degree in Medicine from a renowned Chinese institution. She has pursued extensive postgraduate training and specialized programs in reproductive medicine, refining her knowledge in assisted reproductive technology, reproductive endocrinology, and genetic screening. Her continuous pursuit of academic excellence has positioned her as a leading educator and mentor in reproductive healthcare.

💼 Experience

With a distinguished career spanning over 20 years, Dr. Ma has been instrumental in pioneering and implementing ART techniques. She has successfully led numerous national and provincial medical projects in China, focusing on fertility evaluation, genetic screening, and reproductive health. In addition to her clinical practice, she plays a pivotal role in policy-making and regulatory aspects of reproductive medicine, ensuring the ethical implementation of ART procedures. As an educator, she has trained and mentored countless physicians, enhancing the field of reproductive medicine across China.

🔬 Research Interests On Medicine

Dr. Ma’s research is dedicated to three-level prevention and control of birth defects, fertility preservation in cancer patients, and the application of genetic screening in reproductive health. She explores the mechanisms behind endometriosis, recurrent pregnancy loss, and infertility, aiming to develop innovative treatment protocols. Her contributions to preimplantation genetic testing (PGT) and reproductive immunology have significantly influenced reproductive healthcare in China and beyond.

🏆 Awards and Recognitions

Dr. Ma has been recognized for her outstanding contributions to reproductive medicine and has received multiple accolades at the national and provincial levels. She is an esteemed member of leading reproductive medicine societies and has played a crucial role in shaping policies related to ART in China. She has also been actively involved in national academic conferences, furthering research and clinical advancements in reproductive health.

📚 Publications

Dr. Ma has published over 30 research articles in SCI-indexed and Chinese core journals. Below are some of her notable publications:

  1. Guan, D., Sun, W., Gao, M., Chen, Z., & Ma, X. (2024). Immunologic insights in recurrent spontaneous abortion: Molecular mechanisms and therapeutic interventions. Biomedicine & Pharmacotherapy, 177, p.117082. [Cited by articles]
  2. Liu, L., Liu, Y., Tian, Y., Cao, Y., Wang, T., Mi, S., Yang, R., Liu, S., Ma, X., & Wang, J. (2024). Identification of differentially expressed mRNAs and lncRNAs contributes to elucidation of underlying pathogenesis and therapeutic strategy of recurrent implantation failure. Reproductive Sciences, pp.1-14. [Cited by articles]
  3. Wang, T., Zhang, L., Gao, W., Liu, Y., Yue, F., Ma, X., & Liu, L. (2024). Transcriptome-wide N6-methyladenosine modification profiling of long non-coding RNAs in patients with recurrent implantation failure. BMC Medical Genomics, 17(1), p.251. [Cited by articles]
  4. Guan, D., Zhao, L., Shi, X., Ma, X., & Chen, Z. (2023). Copper in cancer: from pathogenesis to therapy. Biomedicine & Pharmacotherapy, 163, p.114791. [Cited by articles]

🔚 Conclusion

Dr. Xiaoling Ma is a pioneering figure in reproductive medicine, dedicated to advancing ART and genetic screening technologies. Her extensive clinical expertise, innovative research, and leadership in reproductive medicine make her a highly respected figure in her field. Through her work, she continues to impact countless lives, improving fertility treatments and reproductive healthcare policies. Her commitment to teaching, research, and patient care ensures a lasting legacy in reproductive medicine.

Anquan Shang | Medicine | Best Researcher Award

Prof. Anquan Shang | Medicine | Best Researcher Award

The Second People’s Hospital of Lianyungang | China

Prof. Anquan Shang is a distinguished Associate Chief Laboratory Technician and Clinical Laboratory Physician with an H-index of 26. At the age of 39, he has made significant contributions to the field of clinical laboratory diagnostics. As a master’s supervisor, he plays a crucial role in mentoring future medical professionals. He is currently affiliated with Shanghai Jiao Tong University and has extensive experience in tumor marker research and clinical diagnostics.

Profile👤

ORCID

Google Scholar

Scopus

Strengths for the Awards✨

  • Strong Research Productivity 

    • H-index of 26, indicating high citation impact.
    • Over 70 SCI and core journal publications as first or corresponding author.
    • Multiple high-impact factor papers in oncology, microbiology, and immunology.
  • Impressive Funding & Grants 

    • Secured multiple national and provincial-level research grants.
    • Led and participated in 13+ major projects in oncology, infection, and precision diagnostics.
  • Leadership & Recognition 

    • Head of key clinical departments and training programs in prestigious hospitals.
    • Recognized in Shanghai and Jiangsu talent programs, highlighting academic excellence.
  • Significant Innovations & Impact 

    • Contributions to liquid biopsy, tumor biomarkers, and infection diagnostics.
    • 5+ patents, demonstrating translational research impact.
  • Professional Network & Influence 

    • Active in national and international research communities.
    • Reviewer and editor for multiple scientific journals.

🎓 Education

His academic journey began with a specialization in medical laboratory technology at Xiangfan Vocational and Technical College (2005-2008). He then pursued a bachelor’s degree in medical laboratory science at Jiangsu University (2011-2014), followed by a master’s degree in clinical laboratory diagnostics at Ningxia Medical University (2014-2017). He furthered his expertise with a Ph.D. in clinical laboratory diagnostics from Tongji University (2017-2020), establishing a strong foundation for his research career.

🏥 Experience

Currently, he is a postdoctoral researcher in clinical laboratory diagnostics at Ruijin Hospital, affiliated with Shanghai Jiao Tong University (2025-present), focusing on tumor biomarker research. Since 2023, he has led the Clinical Laboratory Medicine Department at Lianyungang Second People’s Hospital, a key clinical specialty in Jiangsu Province. Previously, he completed another postdoctoral fellowship at Tongji University (2020-2022), researching tumor microenvironment and biomarkers. His clinical experience spans roles as a laboratory technician at various hospitals between 2008 and 2014, steadily advancing to leadership positions.

🔬 Research Interests On Medicine

His research focuses on:

1️⃣ Tumor immunology 🧬

2️⃣ Infection microecology and immune microenvironment remodeling 🦠

3️⃣ Precision molecular diagnostics for chronic diseases 🏥

4️⃣ Liquid biopsy techniques for early disease detection 💉

🏆 Awards

He has received numerous prestigious awards, including the Yancheng City Natural Science Achievement Award (3 times), the Yancheng Medical New Technology Introduction Award (5 times), and the Huaihai Science and Technology Progress Award (2nd Prize, twice). From 2019-2022, he was consecutively recognized as an Outstanding Young Scientific Researcher by the Shanghai Medical Association Laboratory Medicine Branch.

📚 Publications

  • Title: Exosomal circPACRGL promotes progression of colorectal cancer via the miR-142-3p/miR-506-3p-TGF-β1 axis
    Authors: A Shang, C Gu, W Wang, X Wang, J Sun, B Zeng, C Chen, W Chang, …
    Publication Year: 2020
    Citations: 372

  • Title: Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils
    Authors: A Shang, W Wang, C Gu, C Chen, B Zeng, Y Yang, P Ji, J Sun, J Wu, …
    Publication Year: 2019
    Citations: 147

  • Title: Exosomal KRAS mutation promotes the formation of tumor-associated neutrophil extracellular traps and causes deterioration of colorectal cancer by inducing IL-8 expression
    Authors: A Shang, C Gu, C Zhou, Y Yang, C Chen, B Zeng, J Wu, W Lu, W Wang, …
    Publication Year: 2020
    Citations: 100

  • Title: Tumor microenvironment: lactic acid promotes tumor development
    Authors: Y Gao, H Zhou, G Liu, J Wu, Y Yuan, A Shang
    Publication Year: 2022
    Citations: 80

  • Title: Exosomal miR-183-5p promotes angiogenesis in colorectal cancer by regulation of FOXO1
    Authors: A Shang, X Wang, C Gu, W Liu, J Sun, B Zeng, C Chen, P Ji, J Wu, …
    Publication Year: 2020
    Citations: 77

  • Title: Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer
    Authors: AQ Shang, J Wu, F Bi, YJ Zhang, LR Xu, LL Li, FF Chen, WW Wang, …
    Publication Year: 2017
    Citations: 77

  • Title: Knockdown of long noncoding RNA PVT1 suppresses cell proliferation and invasion of colorectal cancer via upregulation of microRNA-214-3p
    Authors: AQ Shang, WW Wang, YB Yang, CZ Gu, P Ji, C Chen, BJ Zeng, JL Wu, …
    Publication Year: 2019
    Citations: 70

  • Title: IGF2BP2 promotes the progression of colorectal cancer through a YAP‐dependent mechanism
    Authors: J Cui, J Tian, W Wang, T He, X Li, C Gu, L Wang, J Wu, A Shang
    Publication Year: 2021
    Citations: 62

  • Title: miR‐381‐3p restrains cervical cancer progression by downregulating FGF7
    Authors: A Shang, C Zhou, G Bian, W Chen, W Lu, W Wang, D Li
    Publication Year: 2019
    Citations: 62

  • Title: Vaginal microecological characteristics of women in different physiological and pathological period
    Authors: L Shen, W Zhang, Y Yuan, W Zhu, A Shang
    Publication Year: 2022
    Citations: 59

🔚 Conclusion

With a strong academic background, leadership in clinical laboratory medicine, and groundbreaking research in tumor immunology and molecular diagnostics, he continues to make significant contributions to medical science. His extensive experience, prestigious awards, and influential publications highlight his dedication to advancing clinical diagnostics and improving patient outcomes.

Guoli Li | Medicine | Best Researcher Award

Dr. Guoli Li | Medicine | Best Researcher Award

Researcher | Hunan Provincial People’s Hospital (The First-Affiliated Hospital of Hunan Normal University) | China

Dr. Guoli Li, Ph.D., is an Assistant Professor at Hunan Provincial People’s Hospital and the First Affiliated Hospital of Hunan Normal University, located in Changsha, China. With expertise in Molecular Medicine, Cancer Research, and Nephrology, Dr. Li has contributed extensively to the scientific community, focusing on cutting-edge advancements in medical research.

Profile

Google Scholar

Strengths for the Awards

  • Extensive Research Background:
    Dr. Guoli Li has a strong academic and research foundation in molecular medicine, cancer research, and nephrology, with significant experience at reputable institutions like the University of Texas MD Anderson Cancer Center and Hunan Normal University.
  • Diverse Publication Record:
    Dr. Li has authored numerous high-impact publications in peer-reviewed journals such as Frontiers in Oncology, Genes and Diseases, and BMC Nephrology. These papers cover critical topics like cancer biomarkers, glomerulopathy, and ferroptosis in cancer, demonstrating expertise in innovative and clinically relevant research.
  • Bibliometric Contributions:
    Contributions to bibliometric studies (e.g., research on ferroptosis and mitophagy) highlight Dr. Li’s ability to analyze global research trends, adding to their scholarly influence.

Education 🎓

  • Ph.D. in Biochemistry and Molecular Biology (2013–2017)
    Central South University, Changsha, Hunan, China
  • B.S. in Biotechnology (2008–2012)
    Changchun University of Technology, Changchun, Jilin, China

Experience 💼

  • Research Scientist (09/2020–Present)
    Hunan Provincial People’s Hospital, Hunan Normal University, Changsha, Hunan, China
  • Postdoctoral Fellow (09/2018–08/2020)
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  • Instructor (06/2018–06/2020)
    Guangzhou Medical University, Guangzhou, Guangdong, China
  • Technician (08/2012–08/2013)
    Sansure Biotech Inc., Changsha, Hunan, China

Research Interests On Molecular Medicine🔬

Dr. Li’s research spans:

  • Molecular mechanisms in cancer biology 🧬
  • Nephrology, focusing on lupus nephritis and glomerulopathy 🩺
  • Biomarker identification and therapeutic development 🚑

Awards 🏆

  • 2018: Outstanding Graduate
  • 2016-2017: Excellent Graduate Student
  • 2009-2010: Excellent Student and Excellent Student Leader

Publications 📚

  • Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing
    Authors: G Li, X Guo, L Tang, M Chen, X Luo, L Peng, X Xu, S Wang, Z Xiao, W Yi, …
    Year: 2017
    Citations: 43
  • Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients
    Authors: G Li, X Guo, M Chen, L Tang, H Jiang, JX Day, Y Xie, L Peng, X Xu, J Li, …
    Year: 2018
    Citations: 39
  • What’s the difference between lung adenocarcinoma and lung squamous cell carcinoma? Evidence from a retrospective analysis in a cohort of Chinese patients
    Authors: W Wang, H Liu, G Li
    Year: 2022
    Citations: 26
  • Integrated analysis of promoter mutation, methylation and expression of AKT1 gene in Chinese breast cancer patients
    Authors: J Heng, X Guo, W Wu, Y Wang, G Li, M Chen, L Peng, S Wang, L Dai, …
    Year: 2017
    Citations: 20
  • The research landscape of ferroptosis in cancer: a bibliometric analysis
    Authors: G Li, Y Liang, H Yang, W Zhang, T Xie
    Year: 2022
    Citations: 17
  • Mutation screening of 10 cancer susceptibility genes in unselected breast cancer patients
    Authors: Y Xie, G Li, M Chen, X Guo, L Tang, X Luo, S Wang, W Yi, L Dai, J Wang
    Year: 2018
    Citations: 16
  • Hyperuricemia is an independent risk factor for renal pathological damage and poor prognosis in lupus nephritis patients
    Authors: T Xie, M Chen, X Tang, H Yin, X Wang, G Li, J Li, X Zuo, W Zhang
    Year: 2016
    Citations: 16
  • Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients
    Authors: H Deng, M Chen, X Guo, J Heng, X Xu, L Peng, H Jiang, G Li, JX Day, J Li, …
    Year: 2019
    Citations: 11
  • Bibliometric insights of global research landscape in mitophagy
    Authors: G Li, W Yin, Y Yang, H Yang, Y Chen, Y Liang, W Zhang, T Xie
    Year: 2022
    Citations: 10
  • LINC00467 is upregulated by DNA copy number amplification and hypomethylation and shows ceRNA potential in lung adenocarcinoma
    Authors: W Wang, H Bo, Y Liang, G Li
    Year: 2022
    Citations: 9

Conclusion 📝

Dr. Guoli Li is a passionate scientist and educator committed to advancing medical research and improving clinical outcomes. With numerous prestigious publications, awards, and invitations as a reviewer for reputed journals, Dr. Li continues to contribute profoundly to the global research community. 🌐